Takeda, Japan's largest pharmaceutical company, will provide US$166 million of funding for iPS research over the next ten years.
AstraZeneca has entered a strategic alliance with WuXi AppTech and acquired Takeda's respiratory business.
Asia's largest pharmaceutical company has entered a partnership with Teva to provide generic drugs to Japan.
Through the WIPO Re:Search consortium, Japanese pharmaceutical Takeda plans to share intellectual property assets to facilitate R&D in neglected tropical diseases.
A long-lasting single-dose malaria drug in phase II clinical trials provides hope for malaria-infected patients.
DNDi has formed a consortium with four pharmaceutical companies to hasten the development of drugs for leishmaniasis and Chagas disease.
To meet the growing demand for seasonal flu vaccines, Takeda has added KAKETSUKEN to its list of suppliers.
The collaboration between the National Cancer Center and Takeda is part of a wider academic-industrial effort to develop new medicines.
The ten-year research collaboration to be hosted at Takeda's Shonan Research Center will focus on developing clinical applications for iPS cells.